Sarepta Therapeutics has ended development of a late-phase Duchenne muscular dystrophy (DMD) drug candidate over a safety problem ... development of SRP-5051. Talks with the FDA were another ...
While the International Longshoremen’s Association (ILA) and the United States Maritime Alliance (USMX) resumed Master Contract discussions earlier this month “to discuss all outstanding issues to ...